Galderma Aesthetics Portfolio: Restylane, Sculptra, Dysport and the FDA Record

What is Galderma's full aesthetic portfolio, what does its FDA PMA/BLA approval and post-market safety record show, and how does its 2024 IPO frame it as the #2 global aesthetics company?

Galderma (Zug, Switzerland; SIX: GALD, IPO March 22, 2024) holds 250 FDA PMA supplements under applicant Q-Med AB across four families: P020023 (Restylane Injectable Gel, approved 2003-12-12 as the first FDA-approved hyaluronic-acid dermal filler in the US, 13 supplements), P030050 (Sculptra poly-L-lactic-acid biostimulator, original approval 2004-08-03, 53 supplements), P040024 (the Restylane-L / Perlane / Lyft / Silk / Eyelight workhorse PMA, original 2005-03-25, 133 supplements), and P140029 (Restylane Refyne, Defyne, Kysse, Contour, original 2016-12-09, 51 supplements); product-code concentration is LMH (HA filler, 249) plus PKY (Sculptra PLLA, 1). Galderma also markets Dysport (abobotulinumtoxinA) under drug license BLA125274 (applicant Galderma Laboratories / Ipsen). openFDA MAUDE lists 3,264 reports across Restylane/Sculptra/Perlane brands (2,021 Injury, 325 Other, 27 Malfunction), dominated by Sculptra (~1,839 reports); openFDA FAERS lists 5,517 Dysport reports (context: Botox 76,272, Xeomin 6,098, Jeuveau 3,866); Galderma/Q-Med has zero FDA recalls in the aesthetic extract. Galderma reported 2024 net sales of $4.410B (+9.3%) with Injectable Aesthetics at $2.299B (+9.6%), and Dysport and Sculptra each posted double-digit growth in 2024.

---

How is Galderma's portfolio structured across FDA PMAs, and what is the Restylane/Sculptra approval timeline?

Galderma's aesthetic injectable footprint is built on two primary regulatory structures: the Center for Devices and Radiological Health (CDRH) for its Class III medical devices (dermal fillers and biostimulators), and the Center for Drug Evaluation and Research (CDER) for its biologic neuromodulator (Dysport).

The device-regulated portfolio consists of 250 Premarket Approval (PMA) supplements held under the corporate entity Q-Med AB (a Swedish medical technology company acquired by Galderma in 2011). These approvals are organized into four distinct PMA families:

The Four PMA Families

1. P020023 (The HA Pioneer - Restylane): Originally approved on December 12, 2003, this PMA marks the historic introduction of Restylane Injectable Gel to the United States market. It was the first FDA-approved hyaluronic acid (HA) dermal filler, establishing the modern standard for non-permanent soft-tissue augmentation. This family contains 13 supplements, representing early packaging and formulation iterations.
2. P030050 (The Sculptra Scaffold): Originally approved on August 3, 2004, under the trade name Sculptra, this PMA represents the first FDA-approved poly-L-lactic acid (PLLA) implant. Initially indicated for the restoration of facial fat loss (lipoatrophy) in patients with human immunodeficiency virus (HIV), it was later expanded under supplement 12 (approved July 28, 2009) to cosmetic indications for the correction of shallow to deep nasolabial fold contour deficiencies. This family has accumulated 53 supplements.
3. P040024 (The Restylane Workhorse): Approved on March 25, 2005, this PMA serves as the regulatory anchor for the traditional Restylane gel family, which utilizes non-animal stabilized hyaluronic acid (NASHA) technology. This family contains 133 supplements and handles the broad expansion of indications:
   • Restylane Silk: Approved under supplement S073 (June 13, 2014) for submucosal lip augmentation and perioral rhytids.
   • Restylane Lyft: Approved under supplement S085 (August 31, 2015) for cheek augmentation and midface contour deficiencies. It was subsequently approved for the correction of volume deficit in the dorsum of the hands under supplement S104 (May 21, 2018), representing a key milestone in hand rejuvenation that we profile in our comparison of hand fillers.
   • Restylane Eyelight: FDA-approved in 2023 (P040024/S135) for the correction of infraorbital hollows (tear troughs).
4. P140029 (The Restylane OBT Family): Approved on December 9, 2016, this PMA introduces Optimal Balance Technology (OBT, also marketed globally as XpresHAn Technology), which prioritizes tissue integration and flexibility for dynamic facial movements. This family holds 51 supplements:
   • Restylane Refyne and Defyne: Approved at the original PMA clearance (December 9, 2016) for moderate-to-severe dynamic facial wrinkles and folds. Restylane Defyne was later expanded under supplement S031 (February 1, 2021) for chin augmentation.
   • Restylane Kysse: FDA-approved on May 5, 2020 for lip augmentation and the correction of upper perioral rhytids.
   • Restylane Contour: Approved under supplement S038 (June 28, 2021) for cheek augmentation and midface contour correction.

PMA Product Code and Regulatory Metrics

Within the 250 PMA supplements, the product codes are concentrated in LMH (Dermal Implant, 249 supplements) and PKY (Dermal Implant for Hand Augmentation, 1 supplement). This regulatory footprint is summarized below:

Note: The Eyelight (2023) and Lyft (2015) clearances listed above entered the market as supplements to the P040024 family; exact supplement numbering and FDA decision dates vary by source, but each product's FDA approval and indication are independently verifiable in the PMA database. | P140029 | 2016-12-09 | Refyne, Defyne, Kysse, Contour | OBT (XpresHAn) | LMH | 51 | Dynamic wrinkles, lips, chin, midface |

The Neuromodulator Pathway: Dysport (BLA 125274)

In contrast to the device-regulated fillers, Galderma markets the neurotoxin Dysport (abobotulinumtoxinA) under a Biologics License Application (BLA 125274). The license is held jointly with Ipsen Biopharmaceuticals, Inc., which manufactures the toxin, while Galderma holds the exclusive commercialization rights for aesthetic indications in the United States and other key markets.

• Initial Aesthetic Approval: The FDA approved BLA 125274 on April 30, 2009, for the temporary improvement in the appearance of moderate to severe glabellar lines in adults under 65.
• Dosing Conversion: Dysport units are not interchangeable with other botulinum toxin products. The FDA label notes that a dose of Dysport must not be converted on a 1:1 basis with Botox or Xeomin. In clinical practice, the conversion ratio is typically 2.5:1 or 3:1 (Dysport units to Botox/Xeomin units) due to differences in assay methodology and molecular structure. For a detailed clinical head-to-head, see our Botox vs Dysport comparison.

---

What do the MAUDE (fillers) and FAERS (Dysport) safety records show, and why does Sculptra dominate the MAUDE count?

Evaluating post-market safety requires examining two separate FDA surveillance databases: the Manufacturer and User Facility Device Experience (MAUDE) for medical devices, and the FDA Adverse Event Reporting System (FAERS) for drugs and biologics. Because their reporting frameworks differ, clinical operators must analyze these datasets independently.

MAUDE Device Safety Profile

An extraction of the FDA MAUDE database for device-regulated Galderma and Q-Med aesthetic brands (filtering for "Restylane", "Sculptra", and "Perlane") yields 3,264 total adverse event reports. The dataset displays an injury-heavy profile:

• Injury Reports: 2,021 cases (61.9% of total reports). These represent adverse physiological tissue responses, including swelling, erythema, infection, nodules, and vascular occlusion.
• Other Reports: 325 cases (10.0%). These include patient dissatisfaction, minor bruising, or transient asymmetry.
• Malfunction Reports: 27 cases (0.8%). These typically represent syringe leakage, needle detachment, or extrusion resistance.
• Recall Status: Galderma/Q-Med holds zero FDA recalls within the aesthetic device extract, reflecting a robust quality control and manufacturing standard.

Brand-Specific MAUDE Distribution and the Sculptra Signal

Analyzing the MAUDE data by brand reveals a strong concentration:

MAUDE REPORTS BY GALDERMA DEVICE BRAND (Total: 3,264)
┌────────────────────────────────────────────────────────┐
│ [██████████████████████████████ ] Sculptra (1,839)     │
│ [███████████████] Restylane Family (1,385)             │
│ [█] Perlane / Other (40)                               │
└────────────────────────────────────────────────────────┘

Sculptra accounts for 1,839 reports (representing 56.3% of the entire device dataset). This dominance is not indicative of higher risk but is directly tied to the product's distinct mechanism of action and history:

1. Late-Onset Nodules: As a poly-L-lactic acid (PLLA) biostimulator, Sculptra relies on triggering a controlled, sub-clinical foreign-body inflammatory response to stimulate host collagen production. If the PLLA microparticles aggregate due to insufficient reconstitution, incorrect dilution, or improper placement (e.g., injection too superficial), they can form palpable, non-inflammatory nodules weeks or months post-treatment. This delayed-onset complication is detailed in our guide to Sculptra nodules and lumps.
2. Early Reconstitution Protocols: In the early years of Sculptra's cosmetic use (following the 2004 and 2009 approvals), the manufacturer's instruction label specified reconstitution with 3–5 mL of sterile water, with an option to stand for 2–12 hours. This low dilution ratio contributed to higher rates of nodule formation in clinical practice. Over the past decade, clinical protocols transitioned to higher dilution ratios (typically 7–9 mL of sterile water plus 1–2 mL of lidocaine) and immediate usage, which significantly reduced nodule incidence. This change was formally codified in supplement approvals.
3. Active Surveillance: Because Sculptra's tissue interaction is biostimulatory rather than passive (like hyaluronic acid), clinicians and the manufacturer maintained higher reporting thresholds for any persistent firm areas, swelling, or delayed tissue responses.

FAERS Biologic Safety Profile (Dysport)

Because Dysport is a biological drug, its adverse events are recorded in FAERS. An extraction of the FAERS database for "Dysport" yields 5,517 total reports. To put this volume into clinical context, the table below compares Dysport's reporting history against other FDA-approved neuromodulators:

Note: FAERS contains reports for both therapeutic and cosmetic indications. Botox and Xeomin show higher absolute report numbers in part due to their extensive therapeutic approvals (e.g., spasticity, migraine, overactive bladder) which involve much higher doses (up to 400 units) than cosmetic treatments (typically 20-50 units).

Under the FDA's Adverse Event Reporting System, these numbers represent passive surveillance. They do not prove causality, nor do they establish incidence rates. Instead, they reflect the commercial volume and reporting patterns of each brand.

---

How do the 2024 IPO and $2.3B injectable revenue frame Galderma as the #2 global aesthetics company?

On March 22, 2024, Galderma priced its Initial Public Offering (IPO) at CHF 53 per share — the top of its announced range — and began trading on the SIX Swiss Exchange (ticker: GALD); the shares closed at CHF 64 on the first day of trading, implying a market capitalization of roughly CHF 15 billion (about $17 billion). At the IPO price of CHF 53 the implied market capitalization at listing was about CHF 12.6 billion. It was the largest Swiss IPO since 2017 and marked Galderma's transition from a private equity consortium (led by EQT Partners, which carved the company out from Nestlé in October 2019 at an enterprise value of CHF 10.2 billion, about $11.3 billion) back into a major, publicly traded healthcare giant.

2024 Corporate Financial Performance

Galderma’s 2024 annual report demonstrates strong commercial performance, solidifying its position as the primary competitor to AbbVie’s Allergan Aesthetics:

• Total Corporate Net Sales: $4.410 billion, representing a 9.3% increase year-on-year at constant currency.
• Injectable Aesthetics Net Sales: $2.299 billion, accounting for 52.1% of total corporate revenue, with a 9.6% year-on-year growth rate.
• Key Growth Drivers: The expansion was driven by double-digit growth in Dysport and Sculptra, alongside the launch of new products in international markets (such as Restylane SHAYPE and Restylane Eyelight).

The financial profile shows how Galderma has established a robust three-pillar injectable model (neurotoxin, HA filler family, and biostimulator) that mirrors Allergan's portfolio (Botox, Juvéderm, and Kybella). This corporate structure is analyzed alongside other leading manufacturers in our sibling guides to the AbbVie/Allergan portfolio and the Merz portfolio.

  GALDERMA INJECTABLE REVENUE STRUCTURE (2024 Net Sales: $2.299B)
  ┌────────────────────────────────────────────────────────┐
  │ [████████████████████████████  ] HA Fillers (Restylane) │
  │ [██████████████████ ] Biologics (Dysport)              │
  │ [█████████] Biostimulators (Sculptra)                  │
  └────────────────────────────────────────────────────────┘

Next-Generation Pipeline: Relfydess (RelabotulinumtoxinA) and Alluzience

To sustain its market position, Galderma is executing a multi-year pipeline expansion, focused on ready-to-use liquid neuromodulators:

1. Relfydess (RelabotulinumtoxinA): Also known under the development code QM-1114, this is a novel, ready-to-use liquid formulation of botulinum toxin type A, manufactured with Galderma's PEARL Technology. Unlike Dysport, which requires saline reconstitution, Relfydess is supplied as a stable liquid to eliminate reconstitution variability. Relfydess is already approved in more than 20 markets (including the European Union, the United Kingdom, Australia, and parts of Asia) for the temporary improvement of moderate-to-severe glabellar lines and lateral canthal lines. In the United States it is not yet approved: the FDA accepted the resubmission of Galderma's Biologics License Application (BLA) for relabotulinumtoxinA on February 2, 2026, after an earlier Complete Response Letter limited to manufacturing (CMC) issues. The BLA is supported by the four-trial READY Phase 3 program (more than 1,900 participants), which reported onset as early as Day 1 and duration of effect up to six months. We cover the U.S. regulatory timeline in detail in our Relfydess BLA review.
2. Alluzience: A separate, earlier Galderma ready-to-use liquid botulinum toxin — but a distinct molecule (liquid abobotulinumtoxinA, the same active as Dysport, rather than Relfydess's relabotulinumtoxinA). Alluzience is marketed in the European Union and select international markets and is not approved in the United States.

Clinical Trial Evidence Depth

Galderma’s regulatory filings are supported by extensive clinical evidence. According to ClinicalTrials.gov registry data, Galderma has sponsored 70 aesthetic-focused clinical studies (where the lead sponsor is Galderma Laboratories, L.P. or Q-Med AB). These studies cover indication expansions, comparative rheology trials, and long-term safety evaluations.

---

Restylane Rheology: NASHA vs. OBT Formulation Differences

A critical component of Galderma's clinical utility is the co-existence of two distinct manufacturing technologies for its hyaluronic acid fillers: Non-Animal Stabilized Hyaluronic Acid (NASHA) and Optimal Balance Technology (OBT, XpresHAn). Understanding the rheology of these two platforms is vital for appropriate patient selection and clinical outcomes.

The NASHA Platform (Restylane, Lyft, Silk, Eyelight)

NASHA technology produces a biphasic, highly calibrated gel. The hyaluronic acid is cross-linked with 1,4-butanediol diglycidyl ether (BDDE) to a low degree (approximately 1% modification), and then passed through sizing sieves to create uniform, discrete gel particles.

• Rheological Characteristics: NASHA gels exhibit high elastic modulus ($G'$) and low cohesivity. They behave as firm, cohesive blocks that resist deformation under mechanical stress.
• Water Uptake (Swelling): Gels manufactured via NASHA technology are highly hydrophilic but have a constrained swelling capacity because of the rigid particle boundaries. However, initial hydration must be budgeted during injection to prevent delayed puffiness, particularly in thin-skinned areas.
• Clinical Placement: The high $G'$ makes NASHA fillers (especially Restylane Lyft and Restylane Classic) ideal for deep structural support—such as supraperiosteal malar lifting, pyriform aperture support, jawline definition, or the hand dorsum.

The OBT/XpresHAn Platform (Refyne, Defyne, Kysse, Contour)

OBT technology produces a monophasic, polydensified gel. It varies the degree of cross-linking and utilizes a proprietary process to modify the polymer chain length, yielding a highly flexible network with varying degrees of mesh density.

• Rheological Characteristics: OBT gels are characterized by lower elastic modulus ($G'$) but exceptionally high strain values (high flexibility). They can deform easily with facial expression and return to their original shape without migrating or breaking.
• Tissue Integration: The high cohesivity of OBT fillers allows them to integrate seamlessly between collagen bundles in the subcutaneous and deep dermal layers, moving in tandem with the superficial musculoaponeurotic system (SMAS) and overlying skin.
• Clinical Placement: These properties make OBT fillers the preferred choice for mobile, dynamic areas of the face. Restylane Kysse is optimized for lip movement and soft volume; Restylane Refyne handles superficial dynamic wrinkles; Restylane Defyne provides flexible support in the nasolabial folds and marionette lines; and Restylane Contour offers a soft, natural midface projection that does not appear rigid during smiling.

Rheology Parameter Matrix

---

Clinical Trial Evidence Behind the Approvals

Galderma’s regulatory portfolio is backed by roughly 70 Galderma-sponsored studies on ClinicalTrials.gov. Rather than recapitulate every endpoint, the clinically important point is what each pivotal program established and where its evidence limits lie. (Always confirm specifics against the FDA Summary of Safety and Effectiveness Data for the relevant PMA supplement before relying on them clinically.)

Restylane Kysse (lip augmentation)

The FDA approval of Restylane Kysse rested on a randomized, controlled, evaluator-blinded, multi-center pivotal study in which subjects were randomized to Restylane Kysse versus a no-treatment control. The study met its primary endpoint — a clinically meaningful improvement on a validated lip fullness scale — and supported a duration claim of up to 12 months. Galderma separately reports high subject satisfaction with the "Kysse-ability" (natural movement) of the treated lip. The relevant comparison for a clinic decision is not Kysse versus a specific competitor gel but Kysse's XpresHAn/OBT flexibility versus the stiffer NASHA lip fillers.

Restylane Eyelight (infraorbital hollows)

The Eyelight approval was based on a phase 3 trial in which about 87% of treated subjects showed improvement in under-eye hollows at 3 months, with the product well tolerated in the periorbital zone. Galderma markets duration of up to 18 months for the infraorbital indication. Periorbital injection carries the highest vascular-occlusion risk of any facial filler zone, so the labeling and injection-depth guidance in the SSED matter more than the headline efficacy percentage.

Sculptra (PLLA biostimulator)

Sculptra's mechanism — gradual neocollagenesis driven by poly-L-lactic-acid microparticles — is supported by histologic evidence of new Type I/III collagen deposition over months, which is why the effect builds over a treatment series rather than appearing immediately. Its distinctive safety signal is delayed-onset nodules, which the data tie to reconstitution and placement rather than to the molecule itself; modern higher-dilution protocols (roughly 7–9 mL plus lidocaine) have reduced but not eliminated this risk.

---

Clinical Protocol: Dermal Filler Vascular Occlusion Management

The unit ranges below reflect published consensus guidance for trained injectors and are illustrative, not a prescription. Hyaluronidase potency varies by manufacturer and formulation, and emergency management must follow the individual patient, the provider's scope and training, and current society (ASDS/ASPS) guidance — not a fixed recipe.

Hyaluronic acid dermal fillers, while temporary and reversible, carry the rare but severe risk of accidental intravascular injection. If a bolus of HA enters an arterial vessel, it can cause physical occlusion, leading to tissue ischemia, necrosis, and, in catastrophic cases, blindness (if retrograde flow reaches the ophthalmic artery). Because Galderma's Restylane line is HA-based, it is fully reversible using the enzyme hyaluronidase.

Immediate Action Protocol for Vascular Occlusion

If a provider observes signs of vascular compromise—such as immediate blanching, a reticulated dusky pattern (livedo reticularis), or severe, disproportionate pain—the following intervention must be initiated immediately:

1. Stop Injection Immediately: Discontinue the procedure. Do not remove the needle or cannula until the syringe is disconnected to prevent pulling filler into adjacent vascular beds.
2. Apply High-Dose Hyaluronidase: Inject hyaluronidase (e.g., Hylase or Vitrase) into the affected anatomical area. The clinical protocol utilizes a "high-dose pulsatile" approach:
   • Inject 500 to 1,500 units of hyaluronidase diluted with saline directly into the ischemic zone.
   • Do not limit injection to the exact site of filler placement; infiltrate the entire region of skin discoloration and along the anatomical course of the occluded artery (e.g., angular artery, facial artery).
3. Mechanical Dispersion: Massage the area vigorously to facilitate contact between the enzyme and the HA gel bolus.
4. Promote Vasodilation: Apply warm compresses to the area to encourage local vasodilation and collateral circulation. Apply topical 2% nitroglycerin ointment (if available) under occlusion, monitoring the patient's blood pressure.
5. Re-evaluate and Repeat: Assess capillary refill every 15–20 minutes. Normal capillary refill is 1–2 seconds. If refill remains delayed or livedo reticularis persists, inject an additional 500 units of hyaluronidase. Repeat this cycle until perfusion is fully restored.
6. Adjunctive Therapy: Administer oral aspirin (325 mg) to reduce platelet aggregation on the intravascular filler surface. If periorbital occlusion is suspected (vision changes, ocular pain), immediately refer the patient to an ophthalmologist for emergency retrobulbar or supratrochlear hyaluronidase infiltration.

---

FAQ

Who owns Galderma today, and is it publicly traded?

Galderma is a publicly traded corporation listed on the SIX Swiss Exchange under the ticker symbol GALD. It priced its IPO on March 22, 2024, at CHF 53 per share (closing at CHF 64 on the first day, implying a market capitalization of roughly CHF 15 billion, or about $17 billion). While the company is publicly traded, a consortium of institutional investors led by EQT Partners (which carved the company out from Nestlé in October 2019) remains a major shareholder. The corporate headquarters are located in Zug, Switzerland.

Is Sculptra a Galderma product, and how is its safety record different from Restylane's?

Yes, Sculptra is owned and manufactured by Galderma, with its FDA approvals held under the Q-Med AB subsidiary. Its safety record in the FDA MAUDE database is distinct from Restylane's because it accounts for a higher proportion of reports (1,839 out of 3,264 total reports) that are dominated by delayed-onset subcutaneous nodules. This is directly related to its physical properties as a poly-L-lactic acid (PLLA) particulate suspension that triggers host collagen production. Unlike Restylane (a hyaluronic acid gel that can be dissolved using hyaluronidase), Sculptra is not reversible and relies on precise reconstitution and subdermal placement to minimize nodule formation.

---

Sources

1. FDA Premarket Approval (PMA) Database, P020023 (Restylane Injectable Gel): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P020023
2. FDA Premarket Approval (PMA) Database, P030050 (Sculptra): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P030050
3. FDA Premarket Approval (PMA) Database, P040024 (Restylane Family): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P040024
4. FDA Premarket Approval (PMA) Database, P140029 (Restylane Dynamic OBT Family): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140029
5. FDA Drugs@FDA Database, BLA 125274 (Dysport abobotulinumtoxinA): https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125274
6. Galderma Group AG, Annual Report 2024 (Injectable Net Sales & Financial Performance): https://www.galderma.com/annual-report-2024
7. Galderma Group AG, IPO Pricing Press Release (March 21, 2024): https://www.galderma.com/news/galderma-prices-ipo-chf-53-share-and-will-start-trading-six-swiss-exchange-tomorrow
8. FDA Adverse Event Reporting Systems (FAERS and MAUDE Databases): https://open.fda.gov/apis/
9. U.S. National Institutes of Health ClinicalTrials.gov registry (Lead Sponsor: Galderma): https://clinicaltrials.gov/